Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 14/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26464010 | 0.79 | SLC10A2 (0.39) | SLC10A2 | |
| SCHEMBL9145520 | 0.74 | GRM1 (0.33) | ALDH1A1 | |
| SCHEMBL26464062 | 0.73 | SLC10A2 (0.37) | SLC10A2 | |
| SCHEMBL30885627 | 0.71 | SLC10A2 (0.35) | SLC10A2 | |
| SCHEMBL8949952 | 0.66 | RARG (0.50) | CYP26A1ALDH1A1 | |
| SCHEMBL19789737 | 0.64 | SLC10A2 (0.47) | SLC10A2 | |
| SCHEMBL14596264 | 0.64 | HTR2A (0.37) | HTR1AHTR2AHTR7HTR6ALDH1A1 | |
| SCHEMBL11745042 | 0.64 | ADRA2A (0.43) | CYP26A1DDB1CRBNALDH1A1ADRA2A | |
| SCHEMBL24220258 | 0.63 | SLC10A2 (0.41) | SLC10A2 | |
| SCHEMBL27172647 | 0.62 | CRBN (0.33) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138455-A1 | METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs) | MIRUM PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138455-A1 | METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs) | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885CYP26A1 510/4885DDB1 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.